Evaluation of Regional Gadolinium Retention in the Brain Using QSM With Correlation to Regional DCE MRI Permeability Using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Gadobenic acid (Primary) ; Gadoterate-meglumine (Primary)
- Indications Brain cancer
- Focus Diagnostic use
- 07 Apr 2017 Planned End Date changed from 1 Mar 2020 to 4 Apr 2020.
- 07 Apr 2017 Planned primary completion date changed from 27 Mar 2019 to 4 Apr 2019.
- 07 Apr 2017 Status changed from not yet recruiting to recruiting.